LONDON (Alliance News) - PureTech Health PLC said Tuesday its affiliate, Alivio Therapeutics, has been granted two patents "broadly covering" its inflammation-targeting technology platform.
The patents granted by the US Patent and Trademarks Office "broadly cover compositions of matter and other aspects of the inflammation-targeting microfiber materials with embedded molecules of interest".
According to PureTech, the patents "lay a strong foundation" for Alivio to expand its intellectual property portfolio.
Chief of Research and Strategy Eric Elenko said: "PureTech's mission is to pioneer new categories of medicine that address serious chronic diseases in a highly targeted manner. One area of focus for us is autoimmune disease, such as inflammatory bowel disease and other inflammatory conditions, and Alivio is pioneering inflammation-targeting technology to offer safe and effective treatment options for patients living with these challenging disorders. These new patents validate the uniqueness of Alivio's approach and are foundational to this affiliate's growing pipeline of targeted immunomodulation opportunities."
Shares in PureTech Health closed down 4.9% Tuesday to 157.00 pence each.
PureTech (PRTC)